Patents

Hair Growth Composition Patented by Triple Hair Inc.

Canadian developer of treatments for alopecia develops composition with minoxidil, finasteride and latanoprost.

US Patent No. 11,696,883 B2 (Houfar Sekhavat); Triple Hair Inc., Montreal, has patented a  topical composition that is comprised of 2% to 5% minoxidil; finasteride in an amount greater than or equal to 0.01% and less than 0.225%; and 0.01% to 0.15% latanoprost. The composition is designed for topical application to a scalp.

In related news, Triple Hair Group Inc. in June received a “No Objection Letter” from Health Canada  allowing it to move forward with its Phase III clinical trials on its flagship prescription product, Therapy-07, in Canada. The trials will be aimed at measuring the effectiveness of Therapy-07 on hair regrowth to treat androgenic alopecia, according to the biotech company.

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters